Could a short course of immunotherapy shrink colon cancer before surgery?

This early-phase trial is testing whether giving the immunotherapy drug dostarlimab before surgery can help shrink tumors in people with a specific type of stage III colon cancer (called pMMR/MSS). Ten participants will receive two doses of the drug over six weeks, then undergo surgery. The main goal is to study molecular changes in blood and tumor tissue that might predict a better response. While some patients may benefit, it is not yet known if this approach is better than surgery alone.